アレルギ-性鼻炎のインタ-ル療法

概要

論文の詳細を見る
In the light of several years' experience with Intal therapy in the treatment of allergic rhinitis, we have found that the key factor for successful treatment is to ensure the patient's full understanding of the nature of the drug, prior to the commencement of this therapy. We therefore discuss how patients should be guided and present an analysis of 180 patients to whom Intal was administered. The following results were obtained:1. The age of the patients at the beginning of the treatment period ranged from 3 to 62 years. Sixty-four percent of the male patients were under 20 years of age. In the female group, 75% were between the ages of 10 and 39 years. This distribution is believed to be due to constitutional differences between the sexes.The largest number of patients was in the 10-19 age group, lower in the 20-29 age group, but slightly increasing again in the 30-39 age group. Thereafter, the numbers declined, there being only one male patient in the 60+age group.2. No side effects were observed, except for one patient in whom irritation symptoms necessitated withdrawal of the drug. These results are in accordance with other published work.3. The monthly Intal capsule consumption of 77 patients treated for periods ranging from 6 months to 4 years and 4 months was analysed. The analysis showed that the average monthly requirement necessary to control the symptoms, gradually and steadily decreased over the course of time. These results reconfirm the high degree of efficacy and safety of Intal from an aspect which has not so far been reported in published papers.
耳鼻咽喉科臨床学会の論文

アレルギ-性鼻炎のインタ-ル療法

スポンサーリンク

概要

著者

関連論文

スポンサーリンク